Study to assess the Efficacy of the Chimeric Dopamine-Somatostatin receptor agonist, TBR-760, in adult patients with Non-Functioning Pituitary Adenoma over 52 weeks.

In by ECIR

Study to assess the Efficacy of the Chimeric Dopamine-Somatostatin receptor agonist, TBR-760, in adult patients with Non-Functioning Pituitary Adenoma over 52 weeks.

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

NFPA status-post one TSS with a NFPA remnant of ≥ 10mm

Exclusion Criteria

Has undergone more than one TSS
Has undergone radiation therapy to the head for any reason
Any contraindications to magnetic resonance imaging

Back to Current Studies